DiaMedica Therapeutics Inc. (DMAC)

Market Cap	408.22M +15.3%
Revenue (ttm)	n/a
Net Income	-37.54M
EPS	-0.72
Shares Out	53.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,777
Open	7.91
Previous Close	8.04
Day's Range	7.55 - 8.06
52-Week Range	5.25 - 10.42
Beta	0.91
Analysts	Strong Buy
Price Target	15.50 (+104.76%)
Est. Earnings	Nov 11, 2026

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 35
• Stock Exchange: Nasdaq
• Ticker Symbol: DMAC
• Website: https://www.diamedica.com

Analyst Summary

According to 5 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 104.76% from the latest price.

Price Target

$15.5

(104.76% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error